ClinicalTrials.gg
RecruitingNCT03125642Updated Nov 4, 2026

Auto Stem Cell Transplant for Lymphoma Patients

A Phase 2 interventional study of Etoposide and BCNU in Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2017; still recruiting 9 years 7 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing etoposide in Lymphoma, Non-Hodgkin — 3 open to participants now, 6 under way, 1 of them phase 3. Etoposide · Lymphoma, Non-Hodgkin.

Planned enrollment
8th of 59
150 · median 42
Started
2017
with 1 other
Phase 2
41 of 64
2 open now
Registered
61st of 64
by date
Lead sponsor
2 of 64
Masonic Cancer Center, University of Minnesota

Among the 64 studies testing etoposide in Lymphoma, Non-Hodgkin, this one is the 8th largest by planned enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2017, is one of 41 in phase 2, and was the 61st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 64 studies testing etoposide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etoposide

Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing etoposide in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

03

Conditions studied

  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma

Keywords

  • Lymphoblastic Lymphoma
  • Mature B-cell Lymphomas
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt's/Burkitt's like
  • Mature T-Cell Lymphoma
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible Diseases

    1. Non-Hodgkin's Lymphoma (NHL)

      • Patients with chemo-sensitive confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.
      • Patients in partial or complete remission following cell therapy will also be eligible.
      • NHL patients with resistant or lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial.
      • Lymphoblastic Lymphoma:

        1. All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)
        2. Patients with any high-risk features will be eligible in first complete remission
        3. High risk features include: Stage IV, LDH >2 x , ≥ 2 extranodal sites
      • Mature B-cell Lymphoma

        1. Follicular Lymphoma and other indolent lymphoma in ≥ second CR2/PR2
        2. Diffuse Large B-Cell Lymphoma: in ≥ CR2 or ≥ PR1; a high intermediate or high IPI (≥ 2 for age-adjusted IPI or ≥3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR; transformed lymphoma from FL (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative
        3. Mantle Cell Lymphoma: in first or greater CR or PR
        4. Burkitt's/Burkitt's like: all patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR; patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse
      • Mature T-Cell Lymphoma

        1. Chemosensitive T-cell lymphomas including Primary T-cell not otherwise specified angioimmunoblastic, and ALK-positive anaplastic large cell, will be eligible after initial therapy, whether or not CR is achieved.
        2. Mycosis fungoides/Sezary syndrome will be eligible in ≥CR2/PR2
    2. Hodgkin Lymphoma (HL)

      • Patients with histologically proven HL will be eligible for transplantation after failing prior therapy.
      • Patients with resistant disease (initial or at relapse): those who fail to achieve an objective partial response to three cycles of combination non-cross resistant chemotherapy will not be eligible for transplant in this trial.
      • For stage I/II patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen
      • For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)
      • Patients with any high-risk features will also be eligible, including those who:

        1. fail to achieve complete remission with initial combination chemotherapy
        2. have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or positive) will be eligible - if feasible, persistent disease should be proven by biopsy
      • Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation. The use of up to three cycles of non-cross resistant combination chemotherapy is advised.
      • Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation.
    3. positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:

      • Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period.
      • Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians. For the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor.
      • ≥ 50/µL
      • HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within 30 days of enrollment.
  • Performance Status: Performance Status ≥ 80% for patients ≥ 16 years of age or Lansky Play Score ≥ 80 for patients \< 16 years of age. Note: if poor performance status is due to lymphoma - KPS ≥ 60% or LPS ≥ 60 is acceptable
  • Organ Function

    1. No evidence of serious organ dysfunction that is not attributable to tumor including:

    1. Hematologic:

      • > 8 gm/dL
      • WBC > 2.5 x 109/L with an > 1.5 x 109/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days
      • > 100 x 109/L without transfusion
      • bone marrow cellularity of > 20% with \<5% involvement with tumor
    2. Renal: > 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age
    3. Hepatic: no history of severe prior or ongoing chronic liver disease. Total ≤ 2.0 mg/dl, and alkaline phosphatase \<5x upper limit of normal
    4. Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The by gated cardiac blood flow scan (MUGA) or Echocardiogram must be >40%
    5. Pulmonary: no significant obstructive airways disease ( must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO > 50% of predicted)
    6. Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment
  • Other Inclusion Criteria

    1. At least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
    2. Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate for the duration of treatment
    3. Patients who are carriers of will be included in this study
    4. Voluntary written consent

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding: Females of must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
  • Eligible for any higher priority transplant protocols
  • Chemotherapy resistant disease
  • Unrelated active infection
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    BEAM: NHL & HL

    BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV

    Drug: Etoposide · Drug: BCNU · Drug: AraC · Drug: Melphalan · Procedure: Peripheral blood stem cell transplantation · Biological: G-CSF

  • Experimental
    CBV: HL

    Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients

    Drug: Etoposide · Drug: BCNU · Drug: Cyclophosphamide

  • Experimental
    CY/TBI

    Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM

    Procedure: Peripheral blood stem cell transplantation · Biological: G-CSF · Drug: Cyclophosphamide · Radiation: Total Body Irradiation

Interventions

  • BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4

    Also known as: VP-16

  • DrugCarmustineStudies of CarmustineCarmustine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6

    Also known as: Carmustine

  • DrugCytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2

    Also known as: Cytarabine, cytosine arabinoside, Cytosar-U, Depocyt

  • BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1

    Also known as: Alkeran

  • ProcedurePeripheral blood stem cell transplantation

    All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

    Also known as: PBSC

  • BiologicalGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

    Also known as: filgrastim

  • CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6

    Also known as: Cytoxan

  • RadiationTotal Body Irradiation

    CY/TBI: 165 cGy bid on Day -4, -3, -2, -1

    Also known as: TBI

06

What researchers measure

Primary outcomes

  1. Progression Free Survival Comparison

    Compare progression-free survival (PFS) at 3 years post-transplant for patients who received who received a radiation free preparative regimen to the prior study MT2004-24 where NHL subjects received total body irradiation (TBI) as part of their preparative regimen.

    Time frame: 3 years post transplant

Secondary outcomes

  1. Overall Survival

    Incidence of survival

    Time frame: 3 years post transplant

  2. Treatment related mortality

    Incidence of treatment related mortality

    Time frame: 6 months post transplant

  3. Treatment related mortality

    Incidence of treatment related mortality

    Time frame: 1 year post transplant

  4. Secondary malignancies

    Cumulative incidence of secondary malignancies

    Time frame: 3 years post transplant

  5. Neutrophil engraftment

    Average days to neutrophil engraftment

    Time frame: Day +1 to engraftment

  6. Platelet engraftment

    Average days to platelet engraftment

    Time frame: Day +1 to engraftment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2017 (actual). Primary completion is estimated for Sep 2027, 125 months after the start.

Of 170 non-industry phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 111. This study's planned 125 months is above that.

Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Sep 2027 and completion Apr 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2017
First posted
Apr 24, 2017
StartActual
Apr 20, 2017
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Apr 30, 2028was Apr 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 4, 2026
Study completion
Apr 30, 2027→Apr 30, 2028
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Apr 30, 2027→Apr 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03125642
Responsible party
Sponsor
First posted
Apr 24, 2017
Start date
Apr 20, 2017
Primary completion
Sep 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Timothy Krepski
Contact
tkrepsk1@fairview.org
612-273-2800
Veronika Bachanova, MD
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etoposide · Carmustine · Cytarabine · Melphalan · Granulocyte Colony-Stimulating Factor · Cyclophosphamide

Start the discussion